FAQ

Zdrowie Publiczne i Zarządzanie

Medycyna zindywidualizowana i farmakogenomika w leczeniu schorzeń centralnego układu nerwowego – przyszłość farmakoterapii czy kolejne wyzwanie dla systemu opieki zdrowotnej?

Data publikacji: 2013

Zdrowie Publiczne i Zarządzanie, 2013, Tom 11, Numer 1, s. 59 - 68

https://doi.org/10.4467/20842627OZ.14.006.1616

Autorzy

,
Tomasz Bochenek
Instytut Zdrowia Publicznego, Wydział Nauk o Zdrowiu, Uniwersytet Jagielloński Collegium Medicum, Kraków
https://orcid.org/0000-0001-9915-7267 Orcid
Wszystkie publikacje autora →
Władysław Lasoń
Collegium Medicum Uniwersytetu Jagiellońskiego, Świętej Anny 12, 31-008 Kraków
Wszystkie publikacje autora →

Abstrakt

The personalized medicine and the pharmacogenomics in treatment of central nervous system diseases - future of pharmacotherapy or next challenge for a health care system?

The concept of personalized medicine has become increasingly popular and even “fashionable” within recent years, although the idea of personalization had originated in medicine much earlier than it gained its current label. Providing a therapy which is tailored to needs of a particular patient has been facilitated in selected areas of medicine by successful translation of the human genome and the developments of modern diagnostics and pharmacology. The personalized medicine is an area of development of medical and social sciences. It is also taking position within the health care system and it requires the sound sources of financing. The authors analyze the current status of knowledge on personalized medicine from the health care system’s point of view and setting the special focus on diseases of the central nervous system, including epilepsy. The on-going R&D initiatives from the field of the pharmacogenomics and the personalized medicine have been also presented in this paper

Bibliografia

Clark A.E., Sequence Thyself: Personalized Medicine and Therapies for the Future. 2012 Yale Healthcare Conference. „Yale Journal of Biology and Medicine” 2012; 85: 421–424.

Classen D.C., Pestotnik S.L., Evans R.S. et al., Adverse drug events in hospitalized patients. „JAMA” 1997; 277(4): 301–306.

Cullen D.J., Sweitzer B.J., Bates D.W. et al., Preventable adverse drug events in hospitalized patients: A comparative study of intensive care and general care units. „Crit. Care Med.” 1997; 25(8): 1289–1297.

Lazarou J., Pomeranz B.H., Corey P.N., Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. „JAMA” 1998; 279(15): 1200–1205.

Lee M.-S., Flammer A.J., Lerman L.O., Lerman A., Person- alized Medicine in Cardiovascular Diseases. „Korean Circ. J.” 2012; 42: 583–591.

Gollust S.E., Gordon E.S., Zayac C., Griffin G., Christman M.F., Pyeritz R.E., Wawak L., Bernhardt B.A., Motivations and perceptions of early adopters of personalized genomics: perspective from research participants. „Public Health Genomics” 2012; 15: 22–30.

Burke W., Psaty B.M., Personalized medicine in the era of genomics. „JAMA” 2007; 298: 1682–1684.

Urzędowska M., Angelina Jolie poddała się podwójnej mastektomii. „Mam nadzieję, że inne kobiety skorzystają z mojego doświadczenia”, „Gazeta Wyborcza” 14.05.2013; http://wyborcza.pl/1,75477,13904518,Angelina_Jolie_pod- dala_sie_podwojnej_mastektomii_.html; dostęp: 8.06.2013.

Milejski P., Orzechowska-Juzwenko K., Genetycznie uwarunkowane zaburzenia reakcji farmakodynamicznych i ich kliniczne znaczenie. „Pol. Tyg. Lek.” 1986; 41: 1641–1645.

Sankar R., Teratogenicity of antiepileptic drugs: role of drug metabolism and pharmacogenomics. „Acta Neurol. Scand.” 2007; 116: 65–71.

Faulkner E., Annemans L., Garrison L., Helfand M., Holtorf A.-P., Hornberger J., Hughes D., Li T., Malone D., Payne K., Siebert U., Towse A., Veenstra D., Watkins J., for Personalized Medicine Development and Reimbursement Working Group, Challenges in the Development and Reim- bursement of Personalized Medicine – Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group. „Value in Health” 2012; 15: 1162–1171.

Vignal A., Milan D., San Cristobal M., Eggen A., A review on SNP and other types of molecular markers and their use in animal genetics. „Genet. Sel. Evol.” 2002; 34(33): 275–305.

Roden D.M., Altman R.B., Benowitz N.L., Flockhart D.A., Giacomini K.M., Johnson J.A., Krauss R.M., McLeod H.L., Ratain M.J., Relling M.V., Ring H.Z., Shuldiner A.R., Weinshilboum R.M., Weiss S.T., Pharmacogenetics Research Net- work. „Ann. Intern. Med.” 2006; 145(10): 749–757.

Borowicz K.K., Furmanek-Karwowska K., Sawicka K.M., Morawska M., Gołyska D., Zarczuk R. et al., Mechanizmy oporności na leki w padaczce. „Epileptologia” 2008; 16: 123–132.

Szoeke C.E., Newton M., Wood J.M., Goldstein D., Berkovic S.F., OBrien T.J. et al., Update on pharmacogenetics in epilepsy: a brief review. „Lancet Neurol.” 2006; 5: 189–196.

Helbig I., Mefford H.C., Sharp A.J., Guipponi M., Fich- era M., Franke A.T. et al.: 15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. „Nat. Genet.” 2009; 41(2): 160–162.

Białecka M., Hnatyszyn G., Bielicka-Cymerman J., Droździk M., Znaczenie polimorfizmu genu MDR-1 w patoge- nezie i leczeniu padaczki lekoopornej. „Neurol. Neurochir. Pol.” 2005; 39: 476–481.

Siddiqui A., Kerb R., Weale M.E., Brinkkmann U., SmithA., Goldstein D.B. et al., Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. „N. Engl. J. Med.” 2003; 348: 1442–1448.

Tate S.K., Sisodiya S.M., Multidrug resistance in epilepsy: a pharmacogenomic update. „Expert Opin. Pharmacother.” 2007; 8: 1441–1449.

Sills G.J., Mohanraj R., Butler E., McGindle S., Collier L., Wilson E.A. et al., Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. „Epilep- sia” 2005; 46: 643–647.

Leschziner G., Jorgensen A.L., Andrew T., Pirmohamed M., Williamson P.R., Marson A.G. et al., Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort study. „Lancet Neurol.” 2006; 5: 668–676.

Leschziner G.D., Andrew T., Leach J.P., Chadwick D., Coffey A.J., Balding D.J. et al., Common ABCB1 poly- morphisms are not associated with multidrug resistance in epilepsy using a gene-wide tagging approach. „Pharmaco- genet. Genomics” 2007; 17: 217–220.

Mann M.W., Pons G., Various pharmacogenetic aspects of antiepileptic drug therapy: a review. „CNS Drugs” 2007; 21: 143–164.

Tate S.K., Dependt C., Sisodiya S.M., Cavalleri G.L., Schorge S., Soranzo N.: Genetic predictors of the maximum dose patients receive during clinical use of the antiepilep- tic drugs carbamazepine and phenytoin. „Proc. Natl. Acad. SAci U.S.A.” 2005; 102: 5507–5512.

Ferraro T.N., Dlugos D.J., Buono R.J., Challenges and opportunities in the application of pharmacogenetics to antiepi- leptic drug therapy. „Pharmacogenomics” 2006; 7: 89–103.

Gambardella A., Manna I., Labate A., Chifari R., La Russa A., Serra P. et al., GABA(B) receptor 1 polymorphism (G1465A) is associated with temporal lobe epilepsy. „Neu- rology” 2003; 60: 560–563.

Pirmohamed M., Liu K., Chadwick D., Park B.K., TN- Falpha promotor region gene polymorphisms in carbamazepine hypersensitive patients. „Neurology” 2001; 56: 890–896.

Chung W.H., Hung S.I., Hong H.S., Hsih M.S., Yang L.C., Ho H.C., Wu J.Y., Chen Y.T., Medical genetics: a marker for Stevens-Johnson syndrome. „Nature” 2004; 428(6982): 486.

Jóźwiak S., Lasoń W., Bijak M., Kotulska K., Postępy w badaniach nad genetyką molekularną padaczek. „Neurol. Neurochir. Pol.” 2005; 39: 497–507.

Kwan P., Baum L., Wong V., Ng P.W., Lui C.H., Sin N.C. et al., Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. „Epilepsy Be- hav.” 2007; 11: 112–117.

Delgado-Escueta A.V., Bourgeois B.F., Debate: Does ge- netic information in humans help us treat patients? PRO- genetic information in humans helps us treat patients. CON-genetic information does not help at all. „Epilepsia” 2008; 49 (supl. 9): 13–24.

Depondt C., Shorvon S.D., Genetic association studies in epilepsy pharmacogenomics: lesson learnt and potential applications. „Pharmacogenomics” 2006; 7: 731–745.

Petrovski S., Szoeke C.E., Sheffield L.J., D’Souza W., Huggins R.M., O’Brien T.J., Multi-SNP pharmacogenomic classifier is superior to single-SNP models for predicting drug outcome in complex diseases. „Pharmacogenet. Ge- nomics” 2009; 19(2): 147–152.

Crino P.B., Gene expression, genetics, and genomics in epi- lepsy: some answers, more questions. „Epilepsia” 2007; 48 (supl. 2): 42–50.

Johnson M.D., Floyd J.L., Caprioli R.M., Proteomics in diagnostic neuropathology. „J. Neuropathol. Exp. Neurol.” 2006; 65: 837–845.

Chaurand P., Sanders M.E., Jensen R.A., Caprioli R.M.: Proteomics in diagnostic pathology: profiling and imaging proteins directly in tissue sections. „Am. J. Pathol.” 2004; 165: 1057–1068.

Rybakowski J., Farmakogenomika – nowe podejście do farmakoterapii zaburzeń psychicznych. „Farmakoter. Psychiat. Neurol.” 2001; 4: 313–321.

Suchanek R., Owczarek A., Paul-Samojedny M., Kowalczyk M., Kucia K., Kowalski J., BDNF val66met polymorphism is associated with age at onset and intensity of symptoms of paranoid schizophrenia in a Polish population. „J. Neuropsychiatry Clin. Neurosci.” 2013; 25(1): 88–94.

Paul-Samojedny M., Kowalczyk M., Suchanek R., Owczarek A., Fila-Danilow A., Szczygiel A., Kowalski J., Func- tional polymorphism in the interleukin-6 and interleukin-10 genes in patients with paranoid schizophrenia – a casecontrol study. „J. Mol. Neurosci.” 2010; 42(1): 112–119.

Paul-Samojedny M., Owczarek A., Kowalczyk M., Suchanek R., Palacz M., Kucia K., Fila-Daniłow A., Borkowska P., Kowalski J., Association of interleukin 2 (IL-2), interleukin 6 (IL-6), and TNF-alpha (TNFα) gene polymorphisms with paranoid schizophrenia in a Polish population. „J. Neuropsychiatry Clin. Neurosci.” 2013; 25(1): 72–82.

Hauser J., Farmakogenomika leków przeciwdepresyjnych. „Neuropsychiatria i Neuropsychologia” 2006; 1, 1: 43–48.

FDA. Guidance for Industry. Pharmacogenomic Data Submissions 2005: 25; http://www.fda.gov/cder/guidance/ index.htm; dostęp: 26.06.2013.

EMA. Procedure for European Union guidelines and related documents within the pharmaceutical legislative framework 2009: 16; http://www.emea.europa.eu; dostęp: 26.06.2013.

Flowers C.R., Veenstra D., The Role of Cost-Effectiveness Analysis in the Era of Pharmacogenomics. „Pharmacoeco- nomics” 2004; 22 (8): 481–493.

Informacje

Informacje: Zdrowie Publiczne i Zarządzanie, 2013, s. 59 - 68

Typ artykułu: Oryginalny artykuł naukowy

Tytuły:

Angielski:

The personalized medicine and the pharmacogenomics in treatment of central nervous system diseases - future of pharmacotherapy or next challenge for a health care system?

Autorzy

https://orcid.org/0000-0001-9915-7267

Tomasz Bochenek
Instytut Zdrowia Publicznego, Wydział Nauk o Zdrowiu, Uniwersytet Jagielloński Collegium Medicum, Kraków
https://orcid.org/0000-0001-9915-7267 Orcid
Wszystkie publikacje autora →

Instytut Zdrowia Publicznego, Wydział Nauk o Zdrowiu, Uniwersytet Jagielloński Collegium Medicum, Kraków

Collegium Medicum Uniwersytetu Jagiellońskiego, Świętej Anny 12, 31-008 Kraków

Publikacja: 2013

Status artykułu: Otwarte __T_UNLOCK

Licencja: Żadna

Udział procentowy autorów:

Tomasz Bochenek (Autor) - 50%
Władysław Lasoń (Autor) - 50%

Korekty artykułu:

-

Języki publikacji:

Polski

Liczba wyświetleń: 2794

Liczba pobrań: 2269